{"id":31693,"date":"2014-09-22T12:51:39","date_gmt":"2014-09-22T16:51:39","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=31693"},"modified":"2014-09-22T12:51:39","modified_gmt":"2014-09-22T16:51:39","slug":"nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693","title":{"rendered":"Nektar Therapeutics (NASDAQ:NKTR) Shows Positive Preclinical Data on Kappa Agonist Molecules"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 09\/22\/2014 (wallstreetpr) \u2013 <strong>Nektar Therapeutics (NASDAQ:NKTR)<\/strong> recently <a href=\"#_top\" target=\"_blank\">announced<\/a> results from preclinical studies and characterized analgesic profiles of a many of the kappa opioid receptor agonist molecules which act peripherally. Nektar\u2019s medicinal chemistry platform for small molecule was utilized by the company to create preclinical research candidates.<\/p>\n<p style=\"text-align: justify;\">The analgesic properties of agonist kappa receptors have been well mentioned in the medical literature.\u00a0 Kappa opioid receptors express themselves in the peripheral as well as central nervous systems (CNS) and its activation results in a reduction in pain and inflammation as illustrated in a wide range of preclinical models. However, the therapeutic use of these agonists is limited because of the significant dysphoria related to the activation of these in the CNS. It also causes unwanted side effects like fidgeting, anxiety and restlessness.<\/p>\n<p style=\"text-align: justify;\"><strong>Results of the Research<\/strong><\/p>\n<p style=\"text-align: justify;\">According to Stephen K. Doberstein, Ph.D., Senior vice president and chief scientific officer of Nektar Therapeutics (NASDAQ:NKTR), It has been shown that efficacy could be achieved by kappa opioid receptor molecules while acting peripherally, and minimum side effects seen with centrally acting agonist molecules. With this research, the company will continue to utilize the ability of its medicinal chemistry platform for small molecules to create new molecules that will act peripherally and address various pain conditions.<\/p>\n<p style=\"text-align: justify;\"><strong>15-fold improved therapeutics index<\/strong><\/p>\n<p style=\"text-align: justify;\">Results showed that a series of oral, novel, kappa agonist molecules that act peripherally showcased a therapeutic index which was 15-fold improved as compared to kappa agonist molecules that were not selectively peripheral. The preclinical data is being presented at the American Academy of Pain Management&#8217;s annual meeting.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 09\/22\/2014 (wallstreetpr) \u2013 Nektar Therapeutics (NASDAQ:NKTR) recently announced results from preclinical studies and characterized analgesic profiles of a many of the kappa opioid [&hellip;]<\/p>\n","protected":false},"author":12,"featured_media":31696,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[9453,9452,9451,9454],"stock_ticker":[],"class_list":["post-31693","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-nasdaqnktr","tag-nektar-therapeutics","tag-nektar-therapeutics-nasdaqnktr","tag-stephen-k-doberstein","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nektar Therapeutics (NASDAQ:NKTR) Shows Positive Preclinical Data on Kappa Agonist Molecules - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nektar Therapeutics (NASDAQ:NKTR) Shows Positive Preclinical Data on Kappa Agonist Molecules - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 09\/22\/2014 (wallstreetpr) \u2013 Nektar Therapeutics (NASDAQ:NKTR) recently announced results from preclinical studies and characterized analgesic profiles of a many of the kappa opioid [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-09-22T16:51:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/netk.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"186\" \/>\n\t<meta property=\"og:image:height\" content=\"186\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Steve Hackney\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Steve Hackney\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693\"},\"author\":{\"name\":\"Steve Hackney\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\"},\"headline\":\"Nektar Therapeutics (NASDAQ:NKTR) Shows Positive Preclinical Data on Kappa Agonist Molecules\",\"datePublished\":\"2014-09-22T16:51:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693\"},\"wordCount\":278,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/netk.jpg\",\"keywords\":[\"NASDAQ:NKTR\",\"Nektar Therapeutics\",\"Nektar Therapeutics (NASDAQ:NKTR)\",\"Stephen K. Doberstein\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693\",\"name\":\"Nektar Therapeutics (NASDAQ:NKTR) Shows Positive Preclinical Data on Kappa Agonist Molecules - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/netk.jpg\",\"datePublished\":\"2014-09-22T16:51:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/netk.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/netk.jpg\",\"width\":186,\"height\":186},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nektar Therapeutics (NASDAQ:NKTR) Shows Positive Preclinical Data on Kappa Agonist Molecules\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867\",\"name\":\"Steve Hackney\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g\",\"caption\":\"Steve Hackney\"},\"description\":\"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nektar Therapeutics (NASDAQ:NKTR) Shows Positive Preclinical Data on Kappa Agonist Molecules - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693","og_locale":"en_US","og_type":"article","og_title":"Nektar Therapeutics (NASDAQ:NKTR) Shows Positive Preclinical Data on Kappa Agonist Molecules - Wall Street PR","og_description":"Boston, MA 09\/22\/2014 (wallstreetpr) \u2013 Nektar Therapeutics (NASDAQ:NKTR) recently announced results from preclinical studies and characterized analgesic profiles of a many of the kappa opioid [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-09-22T16:51:39+00:00","og_image":[{"width":186,"height":186,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/netk.jpg","type":"image\/jpeg"}],"author":"Steve Hackney","twitter_misc":{"Written by":"Steve Hackney","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693"},"author":{"name":"Steve Hackney","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867"},"headline":"Nektar Therapeutics (NASDAQ:NKTR) Shows Positive Preclinical Data on Kappa Agonist Molecules","datePublished":"2014-09-22T16:51:39+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693"},"wordCount":278,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/netk.jpg","keywords":["NASDAQ:NKTR","Nektar Therapeutics","Nektar Therapeutics (NASDAQ:NKTR)","Stephen K. Doberstein"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693","url":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693","name":"Nektar Therapeutics (NASDAQ:NKTR) Shows Positive Preclinical Data on Kappa Agonist Molecules - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/netk.jpg","datePublished":"2014-09-22T16:51:39+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/netk.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/09\/netk.jpg","width":186,"height":186},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/nektar-therapeutics-nasdaqnktr-shows-positive-preclinical-data-on-kappa-agonist-molecules-31693#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Nektar Therapeutics (NASDAQ:NKTR) Shows Positive Preclinical Data on Kappa Agonist Molecules"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/3ce02e36ec0c7fc865d70f316a025867","name":"Steve Hackney","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d6e4a33d4904dade1e565fa07bb4bc099f7c12bc3da9ba57311e75086b1e91e8?s=96&d=mm&r=g","caption":"Steve Hackney"},"description":"Steve Hackney is a corporate finance professional with over 14 years of experience in cash management and investing. He earned a Bachelor of Science in Finance from Florida State University and holds a Certified Treasury Professional certification. Steve lives in Orlando, Florida with his family.","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/steve-hackney"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31693","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/12"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=31693"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/31693\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/31696"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=31693"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=31693"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=31693"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=31693"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}